Full Text View  
  Tabular View  
  Contacts and Locations  
  No Study Results Posted  
  Related Studies  
Hypofractionated Radiotherapy for Lung Cancer
This study is currently recruiting participants.
Verified by University of Wisconsin, Madison, September 2008
Sponsored by: University of Wisconsin, Madison
Information provided by: University of Wisconsin, Madison
ClinicalTrials.gov Identifier: NCT00214123
  Purpose

The purpose of this trial is to pilot reducing the duration of radiation treatment for lung cancer patients from 6 to 5 weeks using tomotherapy. Specific patient doses will be based on tumor volume being treated. Modeling has shown that increased biologically effective dose (BED) to tumors can be achieved by shortening the radiation delivery schedule and increasing the dose per fraction. This requires decreasing the total dose to hold lung toxicity constant at each dose per fraction level. This is a major paradigm shift in the treatment in this disease and is projected to result in significant improvements in patient outcome as well as a substantial cost savings.


Condition Intervention Phase
Lung Cancer
Radiation: radiation therapy (radiotherapy)
Phase I

MedlinePlus related topics: Cancer Lung Cancer
U.S. FDA Resources
Study Type: Interventional
Study Design: Prevention, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety Study
Official Title: The Use of Helical Tomotherapy to Achieve Dose-Per-Fraction Escalation in Lung Cancer

Further study details as provided by University of Wisconsin, Madison:

Primary Outcome Measures:
  • Grade 3 pneumonitis lasting greater than 2 weeks [ Time Frame: 90 days post radiotherapy (XRT) ] [ Designated as safety issue: Yes ]

Estimated Enrollment: 60
Study Start Date: June 2004
Estimated Study Completion Date: June 2009
Estimated Primary Completion Date: June 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Bin 1: Experimental
bin assignment based on tumor volume
Radiation: radiation therapy (radiotherapy)
Bin assignment based on tumor volume
Bin 2: Experimental
Bin assignment based on tumor volume
Radiation: radiation therapy (radiotherapy)
Bin assignment based on tumor volume
Bin 3: Experimental
Bin assignment based on tumor volume
Radiation: radiation therapy (radiotherapy)
Bin assignment based on tumor volume
Bin 4: Experimental
Bin assignment based on tumor volume
Radiation: radiation therapy (radiotherapy)
Bin assignment based on tumor volume
Bin 5: Experimental
Bin assignment based on tumor volume
Radiation: radiation therapy (radiotherapy)
Bin assignment based on tumor volume

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Thoracic neoplasm requiring at lest 60 Gy conventional radiotherapy

Exclusion Criteria:

  • Prior bleomycin or gemcitabine chemotherapy
  • Prior thoracic radiotherapy
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00214123

Contacts
Contact: Cancer Connect 800-622-8922

Locations
United States, Wisconsin
University of Wisconsin Hospital and Clinics Recruiting
Madison, Wisconsin, United States, 53792
Contact: Cancer Connect     800-622-8922        
Sponsors and Collaborators
University of Wisconsin, Madison
Investigators
Principal Investigator: Minesh Mehta, MD University of Wisconsin, Madison
  More Information

Responsible Party: University of Wisconsin Comprehensive Cancer Center ( Minesh Mehta )
Study ID Numbers: RO04502
Study First Received: September 13, 2005
Last Updated: September 17, 2008
ClinicalTrials.gov Identifier: NCT00214123  
Health Authority: United States: Institutional Review Board

Study placed in the following topic categories:
Thoracic Neoplasms
Respiratory Tract Diseases
Lung Neoplasms
Lung Diseases

Additional relevant MeSH terms:
Respiratory Tract Neoplasms
Neoplasms
Neoplasms by Site

ClinicalTrials.gov processed this record on January 14, 2009